Age: 65.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Inappropriate schedule of product administration, Incorrect dose administered, No adverse event
Clinical narrative: No adverse event; Immunocompromised patient received 0.25 milliliter booster dose of Moderna COVID-19 Vaccine; Moderna -Primary series 2: Date:13Mar 2022 -LOT 026L21B Moderna Booster: Date: 17Jul2022 was 0.25 mL dose -LOT 051B22A; This spontaneous case was reported by a pharmacist and describes the occurrence of INCORRECT DOSE ADMINISTERED (Immunocompromised patient received 0.25 milliliter booster dose of Moderna COVID-19 Vaccine), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Moderna -Primary series 2: Date:13Mar 2022 -LOT 026L21B Moderna Booster: Date: 17Jul2022 was 0.25 mL dose -LOT 051B22A) and NO ADVERSE EVENT (No adverse event) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 051B22A and 026L21B) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Pfizer COVID-19 Vaccine (First dose and LOT ER8730) on 22-Aug-2021. Past adverse reactions to the above products included No adverse event with Pfizer COVID-19 Vaccine. Concurrent medical conditions included Immunocompromised and Cancer (diagnosis was 1 year ago before receiving Covid- 19 vaccines.).   On 13-Mar-2022, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Jul-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .25 milliliter. On 17-Jul-2022, the patient experienced INCORRECT DOSE ADMINISTERED (Immunocompromised patient received 0.25 milliliter booster dose of Moderna COVID-19 Vaccine) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Moderna -Primary series 2: Date:13Mar 2022 -LOT 026L21B Moderna Booster: Date: 17Jul2022 was 0.25 mL dose -LOT 051B22A). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INCORRECT DOSE ADMINISTERED (Immunocompromised patient received 0.25 milliliter booster dose of Moderna COVID-19 Vaccine), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Moderna -Primary series 2: Date:13Mar 2022 -LOT 026L21B Moderna Booster: Date: 17Jul2022 was 0.25 mL dose -LOT 051B22A) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for INCORRECT DOSE ADMINISTERED (Immunocompromised patient received 0.25 milliliter booster dose of Moderna COVID-19 Vaccine) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Moderna -Primary series 2: Date:13Mar 2022 -LOT 026L21B Moderna Booster: Date: 17Jul2022 was 0.25 mL dose -LOT 051B22A).    Patient past drug history included Shingles. Reporter confirmed that diagnosis was 1 year ago before receiving Covid-19 vaccines. Concomitant medications details were not reported by the reporter. It was reported that patient received other vaccines in the 4 weeks prior to COVID-19 vaccine. On 19-NOV-2022, patient received Moderna Bivalent booster dose Lot 062F22A.  The patient would like to get a second Moderna Bivalent dose, but HCP mentioned that he was not finding any information and asked if there was information on a second bivalent booster dose. Treatment details was not reported by the reporter.   This case was linked to MOD-2023-714585 (Patient Link).